Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases

Related Experiment Video

Updated: May 11, 2026

Spheroid Assay to Measure TGF-β-induced Invasion
09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Rebecca S Muraoka1, Nancy Dumont, Christoph A Ritter

  • 1Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 27232, USA.

The Journal of Clinical Investigation
|June 19, 2002
PubMed

Insights

Blocking transforming growth factor-beta (TGF-beta) signaling with a novel fusion protein reduced breast cancer metastasis. This therapeutic approach decreased tumor cell viability and migration, offering a potential strategy against metastatic carcinomas.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Transforming growth factor-beta (TGF-beta) signaling can paradoxically promote tumor progression in established carcinomas.
  • Understanding TGF-beta's role in metastasis is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the therapeutic potential of a soluble Fc:TGF-beta type II receptor fusion protein (Fc:TbetaRII) in preclinical models of breast cancer metastasis.
  • To evaluate the impact of Fc:TbetaRII on primary tumor growth, apoptosis, cell motility, and metastatic spread.

Main Methods:

  • Administration of Fc:TbetaRII to MMTV-Polyomavirus middle T antigen transgenic mice with primary mammary tumors.
  • Assessment of primary tumor apoptosis, cell motility, intravasation, and lung metastasis.
  • Evaluation of Fc:TbetaRII effects on transplanted 4T1 and EMT-6 mammary tumors in syngeneic mice.
  • Analysis of Akt activity and FKHRL1 phosphorylation.
  • Measurement of tumor microvessel density using a dorsal skin window chamber model.

Main Results:

  • Systemic Fc:TbetaRII administration did not affect primary tumor latency but increased apoptosis in primary tumors.
  • Fc:TbetaRII significantly reduced tumor cell motility, intravasation, and lung metastasis in transgenic and transplantable models.
  • These anti-metastatic effects correlated with the inhibition of Akt activity and FKHRL1 phosphorylation.
  • Fc:TbetaRII did not alter tumor microvessel density.

Conclusions:

  • Blockade of TGF-beta signaling via Fc:TbetaRII effectively reduces tumor cell viability and migratory potential.
  • Fc:TbetaRII represents a promising therapeutic strategy for combating metastatic breast cancer.
  • Targeting TGF-beta signaling warrants further investigation as a treatment for metastatic carcinomas.

More Related Videos

The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior08:12

The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior

Published on: June 12, 2019

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...